-
Clinical trials: beyond efficiency-why are we flying blind?
Greg Koski, Matthew Whalen
Opinion Article: Clinical Investigation
-
Clinical trials: beyond efficiency-why are we flying blind?
Greg Koski, Matthew Whalen
Opinion Article: Clinical Investigation
-
Clinical trials: beyond efficiency-why are we flying blind?
Greg Koski, Matthew Whalen
Opinion Article: Clinical Investigation
-
Clinical trials: beyond efficiency-why are we flying blind?
Greg Koski, Matthew Whalen
Opinion Article: Clinical Investigation
-
Clinical trials: beyond efficiency-why are we flying blind?
Greg Koski, Matthew Whalen
Opinion Article: Clinical Investigation
-
Clinical trials: beyond efficiency-why are we flying blind?
Greg Koski, Matthew Whalen
Opinion Article: Clinical Investigation
-
Quality data collection: paying attention to the details
Julie Pepe, Christina Jackson
Commentary: Clinical Investigation
-
Quality data collection: paying attention to the details
Julie Pepe, Christina Jackson
Commentary: Clinical Investigation
-
Quality data collection: paying attention to the details
Julie Pepe, Christina Jackson
Commentary: Clinical Investigation
-
Quality data collection: paying attention to the details
Julie Pepe, Christina Jackson
Commentary: Clinical Investigation
-
Quality data collection: paying attention to the details
Julie Pepe, Christina Jackson
Commentary: Clinical Investigation
-
Quality data collection: paying attention to the details
Julie Pepe, Christina Jackson
Commentary: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 1: basic biology & therapeutic armamentarium
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 1: basic biology & therapeutic armamentarium
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 1: basic biology & therapeutic armamentarium
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 1: basic biology & therapeutic armamentarium
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 1: basic biology & therapeutic armamentarium
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 1: basic biology & therapeutic armamentarium
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
The Role of Mipomersen Therapy in the Treatment of Familial Hypercholesterolemia
Roda Plakogiannis, Lisa Cioce, Edward A Fisher, James A Underberg
Review: Clinical Trail Outcomes: Clinical Investigation
-
The Role of Mipomersen Therapy in the Treatment of Familial Hypercholesterolemia
Roda Plakogiannis, Lisa Cioce, Edward A Fisher, James A Underberg
Review: Clinical Trail Outcomes: Clinical Investigation
-
The Role of Mipomersen Therapy in the Treatment of Familial Hypercholesterolemia
Roda Plakogiannis, Lisa Cioce, Edward A Fisher, James A Underberg
Review: Clinical Trail Outcomes: Clinical Investigation
-
The Role of Mipomersen Therapy in the Treatment of Familial Hypercholesterolemia
Roda Plakogiannis, Lisa Cioce, Edward A Fisher, James A Underberg
Review: Clinical Trail Outcomes: Clinical Investigation
-
The Role of Mipomersen Therapy in the Treatment of Familial Hypercholesterolemia
Roda Plakogiannis, Lisa Cioce, Edward A Fisher, James A Underberg
Review: Clinical Trail Outcomes: Clinical Investigation
-
The Role of Mipomersen Therapy in the Treatment of Familial Hypercholesterolemia
Roda Plakogiannis, Lisa Cioce, Edward A Fisher, James A Underberg
Review: Clinical Trail Outcomes: Clinical Investigation
-
Approaches to the design of clinical trials for primary sclerosing cholangitis*** Design of clinical trials for primary sclerosing cholangitis
Mohamad H Imam, Keith D Lindor, Jayant A Talwalkar
Clinical Trail Methodology: Clinical Investigation
-
Approaches to the design of clinical trials for primary sclerosing cholangitis*** Design of clinical trials for primary sclerosing cholangitis
Mohamad H Imam, Keith D Lindor, Jayant A Talwalkar
Clinical Trail Methodology: Clinical Investigation
-
Approaches to the design of clinical trials for primary sclerosing cholangitis*** Design of clinical trials for primary sclerosing cholangitis
Mohamad H Imam, Keith D Lindor, Jayant A Talwalkar
Clinical Trail Methodology: Clinical Investigation
-
Approaches to the design of clinical trials for primary sclerosing cholangitis*** Design of clinical trials for primary sclerosing cholangitis
Mohamad H Imam, Keith D Lindor, Jayant A Talwalkar
Clinical Trail Methodology: Clinical Investigation
-
Approaches to the design of clinical trials for primary sclerosing cholangitis*** Design of clinical trials for primary sclerosing cholangitis
Mohamad H Imam, Keith D Lindor, Jayant A Talwalkar
Clinical Trail Methodology: Clinical Investigation
-
Approaches to the design of clinical trials for primary sclerosing cholangitis*** Design of clinical trials for primary sclerosing cholangitis
Mohamad H Imam, Keith D Lindor, Jayant A Talwalkar
Clinical Trail Methodology: Clinical Investigation
-
Missing data in clinical trials: a data interpretation problem with statistical solutions? Interview with James Roger
James Roger
Interview: Clinical Investigation
-
Missing data in clinical trials: a data interpretation problem with statistical solutions? Interview with James Roger
James Roger
Interview: Clinical Investigation
-
Missing data in clinical trials: a data interpretation problem with statistical solutions? Interview with James Roger
James Roger
Interview: Clinical Investigation
-
Missing data in clinical trials: a data interpretation problem with statistical solutions? Interview with James Roger
James Roger
Interview: Clinical Investigation
-
Missing data in clinical trials: a data interpretation problem with statistical solutions? Interview with James Roger
James Roger
Interview: Clinical Investigation
-
Missing data in clinical trials: a data interpretation problem with statistical solutions? Interview with James Roger
James Roger
Interview: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, Iss 9
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, Iss 9
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, Iss 9
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, Iss 9
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, Iss 9
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, Iss 9
Acknowledgements: Clinical Investigation
-
Certolizumab pegol in the treatment of Crohns disease: evidence from the PRECiSE clinical trial program
Ian C Lawrance
Review Article: Clinical Investigation
-
Certolizumab pegol in the treatment of Crohns disease: evidence from the PRECiSE clinical trial program
Ian C Lawrance
Review Article: Clinical Investigation
-
Certolizumab pegol in the treatment of Crohns disease: evidence from the PRECiSE clinical trial program
Ian C Lawrance
Review Article: Clinical Investigation
-
Certolizumab pegol in the treatment of Crohns disease: evidence from the PRECiSE clinical trial program
Ian C Lawrance
Review Article: Clinical Investigation
-
Certolizumab pegol in the treatment of Crohns disease: evidence from the PRECiSE clinical trial program
Ian C Lawrance
Review Article: Clinical Investigation
-
Certolizumab pegol in the treatment of Crohns disease: evidence from the PRECiSE clinical trial program
Ian C Lawrance
Review Article: Clinical Investigation